Vext Science Q3 2026 net loss widens 86% year-over-year to USD 4.88 million

PUBT · 1d ago
Vext Science Q3 2026 net loss widens 86% year-over-year to USD 4.88 million
  • Vext Science’s Q3 2026 net loss widened 86% year-over-year to USD 4.88 million.
  • Revenue rose 18% year-over-year to a record USD 14.9 million.
  • Operating cash flow more than doubled from Q2 2026 to USD 2.37 million as first-half inventory converted to cash.
  • In October, the company listed its Phoenix manufacturing property for sale and began reducing Arizona manufacturing to packaging for its dispensaries.
  • Two additional Ohio dispensaries are expected to open in Columbus and Amelia in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vext Science Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611030630NEWSFILECNPR____20261103_322157_1) on November 03, 2026, and is solely responsible for the information contained therein.